Explore
Validate
LearnABIN566074
antibody from antibodies-online
Targeting: AKR1B10
AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN566074 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Aldo-Keto Reductase Family 1, Member B10 (Aldose Reductase) (AKR1B10) (AA 76-143), (partial) antibody
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 76-143, partial
- Isotype
- IgG
- Antibody clone number
- 1A6
- Vial size
- 100 μg
- Storage
- Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
- Handling
- Aliquot to avoid repeated freezing and thawing.
Submitted references Quantification of the host response proteome after herpes simplex virus type 1 infection.
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Berard AR, Coombs KM, Severini A
Journal of proteome research 2015 May 1;14(5):2121-42
Journal of proteome research 2015 May 1;14(5):2121-42
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY
Human pathology 2014 Apr;45(4):834-43
Human pathology 2014 Apr;45(4):834-43
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
Moriguchi H, Zhang Y, Mihara M, Sato C
Scientific reports 2012;2:280
Scientific reports 2012;2:280
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.
Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, Wardle FC, Flanagan AM
The Journal of pathology 2012 Nov;228(3):274-85
The Journal of pathology 2012 Nov;228(3):274-85
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W, Tsao MS, Liao J, Yang GY
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 May;25(5):758-66
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 May;25(5):758-66
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J
Liver international : official journal of the International Association for the Study of the Liver 2011 Jul;31(6):810-6
Liver international : official journal of the International Association for the Study of the Liver 2011 Jul;31(6):810-6
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2518-28
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2518-28
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS, Grigliatti TA, Reid RE, Riggs KW
The Journal of pharmacology and experimental therapeutics 2010 Dec;335(3):533-45
The Journal of pharmacology and experimental therapeutics 2010 Dec;335(3):533-45
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA
